Education
About Us
Working with TipRanks
Follow Us
PureTech Health (PRTC)
NASDAQ:PRTC
PRTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.30 - $28.79
Previous CloseN/A
Volume2.03K
Average Volume (3M)2.91K
Market Cap
$465.59M
Enterprise Value$11.17B
Total Cash (Recent Filing)$367.31M
Total Debt (Recent Filing)$22.36M
Price to Earnings (P/E)9.1
Beta0.81
Next Earnings
Aug 27, 2025EPS Estimate
-2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.98
Shares Outstanding24,018,946
10 Day Avg. Volume2,422
30 Day Avg. Volume2,907
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-4.93
Enterprise Value/Market Cap23.98
Enterprise Value/Revenue550.94
Enterprise Value/Gross Profit2.59K
Enterprise Value/Ebitda-59.54
Forecast
1Y Price Target
$46.00Price Target Upside134.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
PureTech Health News
See All PRTC News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPRTC announced positive results from the Ph 2b ELEVATE study of LYT-100, which is seen as supportive of a role in the IPF landscape as an improvement to standard of care anti-fibrotics.
Drug DevelopmentLYT-100 demonstrates meaningfully improved efficacy with roughly comparable-to-improved safety compared to standard pirfenidone.
Regulatory ProgressThe company plans to meet with the FDA to align on a Phase 3 study, indicating forward momentum in the development process.
Bears Say
Drug TolerabilityDiscontinuations in the LYT-100 arm were slightly higher than those for pirfenidone.
Investor ConcernsInvestor interest in PRTC stock is limited by the expectation that promising assets will get spun out plus the low liquidity for the ADRs.
Stock LiquidityPRTC stock continues to trade only modestly above cash levels as investors struggle with low liquidity for the ADRs and valuing the 'hub' of the 'hub-and-spoke' R&D model.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
1.45% Other Institutional Investors
98.55% Public Companies and
Individual Investors
PRTC FAQ
What was PureTech Health’s price range in the past 12 months?
PureTech Health lowest stock price was $13.30 and its highest was $28.79 in the past 12 months.
What is PureTech Health’s market cap?
PureTech Health’s market cap is $465.59M.
When is PureTech Health’s upcoming earnings report date?
PureTech Health’s upcoming earnings report date is Aug 27, 2025 which is in 74 days.
How were PureTech Health’s earnings last quarter?
PureTech Health released its earnings results on Apr 30, 2025. The company reported $3.98 earnings per share for the quarter, beating the consensus estimate of -$2.83 by $6.81.
Is PureTech Health overvalued?
According to Wall Street analysts PureTech Health’s price is currently Undervalued.
Does PureTech Health pay dividends?
PureTech Health does not currently pay dividends.
What is PureTech Health’s EPS estimate?
PureTech Health’s EPS estimate is -2.04.
How many shares outstanding does PureTech Health have?
PureTech Health has 24,018,946 shares outstanding.
What happened to PureTech Health’s price movement after its last earnings report?
PureTech Health reported an EPS of $3.98 in its last earnings report, beating expectations of -$2.83. Following the earnings report the stock price went down -1.371%.
Which hedge fund is a major shareholder of PureTech Health?
Currently, no hedge funds are holding shares in PRTC
PureTech Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.00 (134.57% Upside)
$46.00 (134.57% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.70%
12-Months-Change
Fundamentals
Return on Equity
11.96%
Trailing 12-Months
Asset Growth
-13.16%
Trailing 12-Months
Company Description
PureTech Health
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PRTC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements such as successful clinical trial results and FDA approval, alongside challenges like market valuation disconnect and funding requirements for future trials.Read More>PRTC Stock 12 Month Forecast
Average Price Target
$46.00
▲(134.57%Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Zevra Therapeutics
―
Autolus Therapeutics
―
Stoke Therapeutics
―
AbSci
―